Weed (BUDZ) Income from Continuing Operations (2010 - 2026)
Weed (BUDZ) posted quarterly Income from Continuing Operations of 175256.0 for Q1 2026, up 60.21% year-over-year from 109391.26 in Q1 2025, and up 91.74% quarter-over-quarter from 2122328.0 in Q4 2025.
Weed (BUDZ) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Weed's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 175256.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 60.21% year-over-year to 175256.0; the TTM figure through Mar 2026 stood at 2479146.0 (down 217.63% YoY), while the FY2025 annual figure was 2744346.0, down 437.35% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 175256.0, up from 2122328.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 734248.0 in Q3 2023, with the low at 3986741.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 192312.0 (2022), against an average of 989428.18.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 1543.81% in 2022, then soared 124.53% in 2023.
- Weed's Income from Continuing Operations stood at 192312.0 in 2022, then tumbled by 105.07% to 394368.0 in 2023, then surged by 66.22% to 133224.0 in 2024, then tumbled by 1493.05% to 2122328.0 in 2025, then jumped by 91.74% to 175256.0 in 2026.
- Business Quant data shows BUDZ's Income from Continuing Operations at 175256.0 in Q1 2026, 2122328.0 in Q4 2025, and 73946.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Weed | 2.88 Mn | 2.88 Mn | - | -104,132.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,256.00 |
| Dec 31, 2025 | -2.12 Mn |
| Sep 30, 2025 | -73,946.00 |
| Jun 30, 2025 | -107,616.00 |
| Mar 31, 2025 | -440,455.00 |
| Dec 31, 2024 | -133,224.00 |
| Sep 30, 2024 | -95,887.00 |
| Jun 30, 2024 | -110,953.00 |
| Mar 31, 2024 | -170,652.00 |
| Dec 31, 2023 | -394,368.00 |
| Sep 30, 2023 | 734,248.00 |
| Jun 30, 2023 | -3.99 Mn |
| Mar 31, 2023 | -197,014.00 |
| Dec 31, 2022 | -192,312.00 |
| Sep 30, 2022 | -2.99 Mn |
| Jun 30, 2022 | -3.08 Mn |
| Mar 31, 2022 | -3.28 Mn |
| Dec 31, 2021 | -467,504.00 |
| Sep 30, 2021 | -182,101.00 |
| Jun 30, 2021 | -1.22 Mn |